Showing 1-10 of 13 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| ACTin1 for DD: Developing and Testing a Digital Single Session Acceptance and Commitment Therapy Intervention for Type 1 Diabetes Distress | Duke University | Max Roberts | Improving Lives | 01-April-2026 to 31-March-2029 | $241.710,00 |
| Pilot Testing a Digital Single Session Intervention for Diabetes Distress | Duke University | Max Roberts | Improving Lives | 01-October-2026 to 30-September-2027 | $110.000,00 |
| Changing the T1DE: A randomized controlled trial comparing ACT to supportive diabetes counseling | Duke University | Rhonda Merwin | Improving Lives | 01-July-2022 to 30-June-2027 | $2.758.224,22 |
| Development and Preclinical Assessment of a Biovascular Pancreas | Humacyte | Kaleb Naegeli | Cures | 01-April-2023 to 28-February-2027 | $863.333,00 |
| Adult T1D Detection at Geisinger | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-July-2023 to 30-June-2027 | $1.033.123,00 |
| Advancing T1D Detection and Care Through AI | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-February-2025 to 31-October-2026 | $345.083,00 |
| JDRF Cures Patient Preference Study in Type 1 Diabetes | RTI International | Kelley Myers | Transportfolio | 01-July-2023 to 31-March-2027 | $831.600,00 |
| The Development of 3-β-hydroxybutyrate binding protein based electrochemical micro-sensor and its application for CKM system | The University of North Carolina at Chapel Hill | Koji Sode | Improving Lives | 01-October-2022 to 30-September-2026 | $799.999,96 |
| Engineering B Cell–Targeted Microparticles to Induce Regulatory Immunity in Type 1 Diabetes | The University of North Carolina at Chapel Hill | Kristy Ainslie | Cures | 01-April-2026 to 31-March-2027 | $200.000,00 |
| Structure-switching Proteins for Continuous In Vivo C-peptide Monitoring | The University of North Carolina at Chapel Hill | Netz Arroyo | Cures | 01-October-2026 to 30-September-2029 | $892.203,85 |